PT DiagnosLab Utama Tbk (Diagnos) launched Cervigene and its digital service platform, DNA and Me 2.0. These two things mark a new era in molecular and digital health services with a focus on convenience, efficiency and affordability for customers.
Cervigene is a revolutionary HPV virus examination method using urine-based molecular technology. It offers a convenient alternative to the traditional swab Pap smear method. With a very affordable price that can reach only 50% of conventional examination methods on the market, Cervigene is expected to be a solution for millions of women in Jakarta for early detection of the HPV virus.
Diagnos targets to be able to serve 1% of the female population in Jakarta. The hope is that this can achieve a contribution from this examination of up to 15% of the company’s total revenue target in 2024. Just so you know, the number of women in Jakarta will reach 5.3 million people in 2022.
On the other hand, DNA and Me 2.0 is a digital service platform that offers nutrogenomic-based genetic examinations that support a healthy lifestyle. This platform is also equipped with a free doctor chat service and integrated lab tests.
“We believe that every individual has the right to access quality and affordable health services,” said Dr Ricky Tjahjadi, VP Medical Diagnoses, in a written statement, Thursday (7/3). “With Cervigene and DNA and Me 2.0, we are committed to providing services that are not only innovative and efficient, but also friendly to people’s pockets.” (Z-2)
#Diagnos #Targets #Revenue #Growth #Services
